July 11, 2025 a 01:01 pm
JNJ: Analysts Ratings - Johnson & Johnson
Johnson & Johnson has been a stable force within the healthcare sector, renowned for its diversified product offerings across consumer health, pharmaceuticals, and medtech. The company continues to leverage its position by fostering innovation and maintaining steady financial performance, making it a robust choice for long-term investors. However, tracking the sentiment and recommendations from analysts can provide insight into how short-term outlooks are shaping up among financial circles.
Historical Stock Grades
As of June 2025, analyst ratings for Johnson & Johnson reveal a balanced outlook. The ratings indicate a stability in the perception of the stock, with a generally favorable bias as most analysts have maintained positive recommendations over time.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 7 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The total number of ratings over recent months has shown consistent interest, with minor fluctuations in strong buy and buy categories.
- Hold ratings have remained steady, reflecting a cautious yet stable outlook among analysts.
- Minor fluctuations in buy ratings suggest analysts are cautiously optimistic but recognize the need for careful assessment given the current market conditions.
Percentage Trends
The percentage distribution of analyst ratings reveals some intriguing trends over the recent months:
- Strong Buy ratings have maintained a consistent representation, roughly holding at around 18% of total recommendations.
- Buy ratings have slightly decreased from the prior month, highlighting a cautious stance among some analysts.
- Hold ratings dominate the sentiment, capturing a larger proportion, suggesting analysts prefer a non-committal position at present.
- No sell or strong sell ratings indicates confidence in the company's current strategies and market position.
Latest Analyst Recommendations
Recent analyst recommendations indicate both maintenance of current outlooks and some adjustments based on recent market developments:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-05 | Outperform | Outperform | RBC Capital |
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-17 | Equal Weight | Equal Weight | Barclays |
| 2025-04-16 | Outperform | Outperform | Raymond James |
| 2025-04-16 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
There are notable adjustments in recommendations reflecting possible shifts in market sentiment:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-09 | Buy | Neutral | Goldman Sachs |
| 2024-07-23 | Neutral | Outperform | Daiwa Capital |
| 2024-04-18 | Buy | Hold | HSBC |
| 2023-12-13 | Equal Weight | Overweight | Wells Fargo |
Interpretation
The current market analysis reveals a balanced sentiment around Johnson & Johnson. Recent analyst adjustments suggest a measured approach, indicative of both confidence in long-term resilience and caution towards immediate market conditions. Stability in ratings combined with minimal sell recommendations underscores a sustained trust in the company’s ongoing strategies. Despite this relative stability, slight shifts toward hold ratings reflect a pragmatic view among analysts, hinting at a cautious optimism tempered by market realities.
Conclusion
Johnson & Johnson continues to be a noteworthy entity within the healthcare industry. Despite fluctuations in analyst sentiment, the corporation maintains a strong reputation, confirming both opportunities and inherent market risks. Current trends display a prudent yet optimistic outlook, with analysts advocating for watchful investment strategies. While buy ratings indicate confidence in operational capacities, increasing hold recommendations point to vigilance amidst market fluctuations. Overall, JNJ appears positioned for sustained performance, albeit within guarded analyst sentiment.